Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Journal of Endocrinological Investigation
Erschienen in: Journal of Endocrinological Investigation 10/2016

01.10.2016 | Short Review

Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any)

verfasst von: L. Bartalena, L. Chiovato, P. Vitti

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 10/2016

Einloggen, um Zugang zu erhalten

Abstract

Graves’ disease is the most common cause of hyperthyroidism in iodine-replete areas. Although progress has been made in our understanding of the pathogenesis of the disease, no treatment targeting pathogenic mechanisms of the disease is presently available. Therapies for Graves’ hyperthyroidism are largely imperfect because they are bound to either a high rate of relapsing hyperthyroidism (antithyroid drugs) or lifelong hypothyroidism (radioiodine treatment or thyroidectomy). Aim of the present article is to offer a practical guidance to the reader by providing evidence-based answers to frequently asked questions in clinical practice.
Literatur
1.
2.
Bartalena L (2013) Diagnosis and management of Graves disease: a global overview. Nat Rev Endocrinol 9:724–734PubMedCrossRef
3.
Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves’ disease: a 2014 update. J Endocrinol Invest 37:691–700PubMedCrossRef
4.
Hammerstad SS, Tomer Y (2015) Epidemiology and genetic factors in Graves’ disease and Graves’ ophthalmopathy. In: Bahn RS (ed) Graves’ disease. A comprehensive guide for clinicians. Springer, New York, pp 21–37
5.
Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P (2015) Role of genetic and non-genetic factors in the etiology of Graves’ disease. J Endocrinol Invest 38:283–294PubMedCrossRef
6.
7.
Marinò M, Latrofa F, Menconi F, Chiovato L, Vitti P (2015) An update on the medical treatment of Graves’ hyperthyroidism. J Endocrinol Invest 37:1041–1048CrossRef
8.
9.
10.
Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Torring O (2008) TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol 158:69–75PubMedCrossRef
11.
Menconi F, Leo M, Vitti P, Marcocci C, Marinò M (2015) Total thyroid ablation in Graves’ orbitopathy. J Endocrinol Invest 38:809–815PubMedCrossRef
12.
Burch HB, Burman KD, Cooper DS (2012) A 2011 survey of clinical practice patterns in the management of Graves’ disease. J Clin Endocrinol Metab 97:4549–4558PubMedCrossRef
13.
Bartalena L, Burch HB, Burman KD, Kahaly GJ (2016) A 2013 European survey of clinical practice patterns in the management of Graves’ disease. Clin Endocrinol (Oxf) 84:115–120CrossRef
14.
Glinoer D, Hesch D, Lagasse R, Laurberg P (1987) The management of hyperthyroidism due to Graves’ disease in Europe in 1986. Results of an international survey. Acta Endocrinol (Copenh) 285(suppl):3–23
15.
Solomon B, Glinoer D, Lagasse R, Wartofsky L (1990) Current trends in the management of Graves’ disease. J Clin Endocrinol Metab 70:1518–1524PubMedCrossRef
16.
Wartofsky L, Glinoer D, Lagasse R, Solomon B (1991) Differences and similarities in the diagnosis and treatment of diffuse goiter in Europe, Japan and the United States. Thyroid 1:129–135PubMedCrossRef
17.
Emiliano AB, Governale L, Parks M, Cooper DS (2010) Shifts in propylthiouracil and methimazole prescribing practices: antithyroid drug use in the United States from 1991 to 2008. J Clin Endocrinol Metab 95:2227–2233PubMedPubMedCentralCrossRef
18.
Sidibé EH (2007) Thyréopathies en Afrique subsaharienne (French). Cahiers Santé 17:33–39
19.
Ahmed ME, El Wasila AA, Sanhouri M, Yagi K (1993) Surgical management of toxic goiter in Khartoum. Trop Geogr Med 45:124–125PubMed
20.
Laurberg P, Cooper DS (2015) Antithyroid drug therapy in patients with Graves’ disease. In: Bahn RS (ed) Graves’ disease. A comprehensive guide for clinicians. Springer, New York, pp 65–82
21.
Abraham P, Avenell A, Park CM, Watson WA, Bevan JS (2005) A systematic review of drug therapy for Graves’ hyperthyroidism. Eur J Endocrinol 153:489–498PubMedCrossRef
22.
Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN (2011) Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21:593–646CrossRef
23.
Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM (1994) Treatment of Graves’ disease with block-and-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. Q J Med 87:337–341PubMed
24.
Elbers L, Mourits M, Wiersinga W (2011) Outcome of very long-term treatment with antithyroid drugs in Graves’ hyperthyroidism associated with Graves’ orbitopathy. Thyroid 21:279–283PubMedCrossRef
25.
Azizi F, Ataie L, Hedayati M, Mehrabi Y, Shekholeslami F (2005) Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol 152:695–701PubMedCrossRef
26.
Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M (2008) Long-term follow-up of patients with hyperthyroidism due to Graves’ disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. J Endocrinol Invest 31:866–872PubMedCrossRef
27.
Laurberg P, Berman BC, Andersen S, Bulow Pedersen I (2011) Sustained control of Graves’ hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves’ orbitopathy. Thyroid 21:951–956PubMedCrossRef
28.
29.
Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A (1997) Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid 7:369–375PubMedCrossRef
30.
Piantanida E, Lai A, Sassi L, Gallo D, Spreafico E, Tanda ML, Bartalena L (2015) Outcome prediction of treatment of Graves’ hyperthyroidism with antithyroid drugs. Horm Metab Res 47:767–772PubMedCrossRef
31.
Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S (2002) Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves’ disease. Eur J Endocrinol 147:583–589PubMedCrossRef
32.
Wang PW, Chen IY, Juo SH, Hsi E, Cy Hsieh (2012) Genotype and phenotype predictors of relapse of Graves’ disease after antithyroid drug withdrawal. Eur Thyroid J 1:251–258PubMedPubMedCentral
33.
Mohlin E, Filipsson Nystrom H, Eliasson M (2014) Long-term prognosis after medical treatment of Graves’ disease in a northern Swedish population 2000–2010. Eur J Endocrinol 170:419–427PubMedCrossRef
34.
Glinoer D, de Nayer P, Bex M, The Belgian Collaborative Study Group on Graves’ disease (2001) Effects of L-thyroxine administration, TSH receptor antibodies and smoking on the risk of recurrence in Graves’ hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 144:475–483PubMedCrossRef
35.
Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR (2002) Does smoking increase relapse rates in Graves’ disease? J Endocrinol Invest 25:152–157PubMedCrossRef
36.
Rotondi M, Cappelli C, Pirali B, Pirola I, Magri F, Fonte R, Castellano M, Agabiti Rosei E, Chiovato L (2008) The effect of pregnancy on subsequent relapse from Graves’ disease after a successful course of antithyroid drug therapy. J Clin Endocrinol Metab 93:3985–3988PubMedCrossRef
37.
Vos XG, Endert E, Zwinderman K, Tijssen JGP, Wiersinga WM (2016) Predicting the risk of recurrence before the start of antithyroid drug therapy in patients with Graves’ hyperthyroidism. J Clin Endocrinol Metab. doi:10.​1210/​jc.​2015-3644 PubMed
38.
Watanabe N, Narimatsu H, Yoshimura Noh J, Yamaguchi T, Kobayashi K, Kami M, Kunii Y, Mukasa K, Ito Ku, Ko Ito (2012) Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves’ disease. J Clin Endocrinol Metab 97:E49–E53PubMedCrossRef
39.
Yang J, Zhu Y-J, Zhong J-J, Zhang J, Weng W-W, Liu Z-F, Xu Q, Dong M-J (2016) Characteristics of antithyroid drug-induced agranulocytosis in patients with hyperthyroidism: a retrospective analysis of 114 cases in a single institution in China involving 9690 patients referred for radioiodine treatment over 15 years. Thyroid 26:627–633PubMedCrossRef
40.
Nakamura H, Maiyauchi A, Miyawaki N, Imagawa J (2013) Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. J Clin Endocrinol Metab 98:4776–4783PubMedCrossRef
41.
Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, Ito M, Amino N, Miyauchi A (2009) Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than 15 mg daily. Thyroid 19:559–563PubMedCrossRef
42.
Kobayashi S, Noh JY, Mukasa K, Kunii Y, Watanabe N, Matsumoto M, Ohye H, Suzuki M, Yoshihara A, Iwaku K, Sugino K, Ito K (2014) Characteristics of agranulocytosis as an adverse effects of antithyroid drugs in the second or later course of treatment. Thyroid 24:796–801PubMedCrossRef
43.
Robinson J, Richardson M, Hickey J, James A, Pearce SH, Ball SG, Quinton R, Morris M, Miller M, Perros P (2014) Patient knowledge of antithyroid drug-induced agranulocytosis. Eur Thyroid J 3:245–251PubMedPubMedCentral
44.
Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH (2014) Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. Br J Clin Pharmacol 78:619–629PubMedPubMedCentralCrossRef
45.
Yang J, Li LF, Xu Q, Zhang J, Weng W-W, Zhu YJ, Dong MJ (2015) Analysis of 90 cases of antithyroid drug-induced severe hepatoxicity over 13 years in China. Thyroid 25:278–283PubMedCrossRef
46.
Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, Rivkees SA, Ross D, Sosa JA, Stan MN (2009) The role of propylthiouracil in the management of Graves’ disease in the adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 19:673–674PubMedCrossRef
47.
48.
Vaidya B, Williams GR, Abraham P, Pearce SHS (2008) Radioiodine treatment for benign thyroid disorders: results of a nationwide survey of UK endocrinologists. Clin Endocrinol (Oxf) 68:814–820CrossRef
49.
Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, Rossi G, Ceccarelli C, Vitti P, Pinchera A, Bartalena L, Martino E (2010) Impact of lithium on efficacy of radioactive iodine therapy for Graves’ disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. J Clin Endocrinol Metab 95:201–208PubMedCrossRef
50.
Martin NM, Patel M, Nijher GMK, Misra S, Murphy E, Meran K (2012) Adjuvant lithium therapy improves the efficacy of radioactive iodine treatment in Graves’ and toxic nodular disease. Clin Endocrinol (Oxf) 77:621–627CrossRef
51.
Traisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nystrom E, Ponjavic V, Taube A, Torring O, Wallin G, Asman P, Lundell G (2009) Thyroid-associated ophthalmopathy after treatment for Graves’ hyperthyroidism with antithyroid drugs or iodine-131. J Clin Endocrinol Metab 94:3700–3707PubMedCrossRef
52.
Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A (1998) Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Engl J Med 338:73–78PubMedCrossRef
53.
Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NC (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464–3470PubMedCrossRef
54.
Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, On behalf of the European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5:9–26PubMedPubMedCentralCrossRef
55.
Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L (2010) Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J Clin Endocrinol Metab 95:1333–1337PubMedCrossRef
56.
Shiber S, Stiebel-Kakish H, Shimon I, Grossman A, Robenshtok E (2014) Glucocorticoid regimens for prevention of Graves’ ophthalmopathy progression following radioiodine treatment: systematic review and meta-analysis. Thyroid 24:1515–1523PubMedCrossRef
57.
Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P (1998) Mortality after treatment of hyperthyroidism with radioactive iodine. N Engl J Med 338:712–718PubMedCrossRef
58.
Metso S, Jaatinen P, Huhtala H, Auvinen A, Oksala H, Salmi J (2007) Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab 92:2190–2196PubMedCrossRef
59.
La Cour JL, Jensen LT, Vej-Hansen A, Nygaard B (2015) Radioiodine therapy increases the risk of cerebrovascular events in hyperthyroid and euthyroid patients. Eur J Endocrinol 172:771–778PubMedCrossRef
60.
Hieu TT, Russell AW, Cuneo R, Clark J, Kron T, Hall P, Doi SA (2012) Cancer risk after medical exposure to radioactive iodine in benign thyroid disease: a meta-analysis. Endocr Relat Cancer 19:645–655PubMedCrossRef
61.
Ryodi E, Metso S, Jaatinen P, Huhtala H, Saaristo R, Valimaki M, Auvinen A (2015) Cancer incidence and mortality in patients treated either with RAI or thyroidectomy for hyperthyroidism. J Clin Endocrinol Metab 100:3710–3717PubMedCrossRef
62.
Boelaert K, Miasonneuve P, Torlinska B, Franklyn JA (2013) Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. J Clin Endocrinol Metab 98:1869–1882PubMedCrossRef
63.
Canale D, Ceccarelli C, Cagliaresi C, Moscatelli A, Gavioli S, Santini P, Elisei R, Vitti P (2015) Effects of radioiodine treatment for differentiated thyroid cancer on testis function. Clin Endocrinol (Oxf) 82:295–299CrossRef
64.
Ceccarelli C, Canale D, Battisti P, Cagliaresi C, Moschini C, Fiore E, Grasso L, Pinchera A, Vitti P (2006) Testicular function after 131I therapy for hyperthyroidism. Clin Endocrinol (Oxf) 65:446–452CrossRef
65.
Genovese BM, Noureldine SI, Gleeson EM, Tufano RP, Kandil E (2013) What is the best definitive treatment for Graves’ disease? A systematic review of the existing literature. Ann Surg Oncol 20:660–667PubMedCrossRef
66.
Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS (2013) Comparative effectiveness of therapies for Graves’ hyperthyroidism: a systematic review and network meta-analysis. J Clin Endocrinol Metab 98:3671–3677PubMedPubMedCentralCrossRef
67.
Guo Z, Yu P, Liu Z, Si Y, Jin M (2013) Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves’ disease: a meta-analysis of randomized clinical trials. Clin Endocrinol (Oxf) 79:739–746
68.
Grodski S, Stalberg P, Robinson BG, Delbridge LW (2007) Surgery versus radioiodine as definitive management for Graves’ disease: the role of patient preference. Thyroid 17:157–160PubMedCrossRef
69.
Ting HH, Brito JP, Montori VM (2014) Shared decision making. Science and action. Circ Cardiovasc Qual Outcomes 7:323–327PubMedCrossRef
70.
Brito JP, Castaneda-Guarderas A, Gionfriddo MR, Singh Ospina N, Maraka S, Dean DS, Castro RM, Fatourechi V, Gharib H, Stan MN, Branda ME, Bahn RS, Montori VM (2015) Development and pilot testing of an encounter tool for shared decision making about the treatment of Graves’ disease. Thyroid 25:1191–1198PubMedCrossRef
71.
Bartalena L (2011) The dilemma of how to manage Graves’ hyperthyroidism in patients with associated orbitopathy. J Clin Endocrinol Metab 96:592–599PubMedCrossRef
72.
Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R (1989) Amelioration of eye changes of Graves’ ophthalmopathy by achieving euthyroidism. Acta Endocrinol (Copenh) 121(suppl 2):185–189
73.
Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) Consensus statement of the European Group on Graves’ Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 158:273–285PubMedCrossRef
74.
Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F (2015) Effects of treatment modalities for Graves’ hyperthyroidism on Graves’ orbitopathy: a 2015 Italian Society of Endocrinology consensus statement. J Endocrinol Invest 38:481–487PubMedPubMedCentralCrossRef
75.
Menconi F, Marinò M, Pinchera A, Rocchi R, Mazzi B, Nardi M, Bartalena L, Marcocci C (2007) Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves’ orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 92:1653–1658PubMedCrossRef
76.
Leo M, Marcocci C, Pinchera A, Nardi M, Megna L, Rocchi R, Latrofa F, Altea MA, Mazzi B, Sisti E, Profilo MA, Marinò M (2013) Outcome of Graves’ orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab 97:E44–E48CrossRef
77.
Moleti M, Violi MA, Montanini D, Trombetta C, Di Bella B, Sturniolo G, Presti S, Alibrandi A, Campenni A, Baldari S, Trimarchi F, Vermiglio F (2014) Radioiodine ablation of post-surgical remnants after treatment with recombinant human TSH (rhTSH) in patients with moderate-to-severe Graves’ orbitopathy (GO): a prospective, randomized, single blind clinical trial. J Clin Endocrinol Metab 99:1783–1789PubMedCrossRef
78.
Stagnaro-Green A (2015) Graves’ disease and pregnancy. In: Bahn RS (ed) Graves’ disease. A comprehensive guide for clinicians. Springer, New York, pp 167–178
79.
De Groot L, Abalovich M, Alexander EA, Amino N, Barbour L, Cobin RH, Eastman CJ, Lazarus JH, Luton D, Mandel SJ, Mestman J, Rovet J, Sullivan S (2012) Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97:2543–2565PubMedCrossRef
80.
Stagnaro-Green A, Abalovich M, Alexander E, Azizi F, Mestman J, Negro R, Nixon A, Pearce EN, Soldin OP, Sullivan S, Wiersinga W (2011) Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid 21:1081–1125PubMedPubMedCentralCrossRef
81.
Fould N, Walpole I, Elmslie F, Mansour S (2005) Carbimazole embryopathy: an emerging phenotype. Am J Med Genet A 132A:130–135CrossRef
82.
Bowman P, Osborne NJ, Sturley R, Vaidya B (2012) Carbimazole embryopathy: implications for the choice of antithyroid drugs in pregnancy. Q J Med 105:189–193CrossRef
83.
Cooper DS, Rivkees SA (2009) Putting PTU in perspective. J Clin Endocrinol Metab 94:1881–1882PubMedCrossRef
84.
Linding Andersen S, Olsen J, Wu CS, Laurberg P (2013) Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J Clin Endocrinol Metab 98:4373–4381CrossRef
85.
Linding Andersen S, Olsen J, Wu CS, Laurberg P (2014) Severity of birth defects after propylthiouracil exposure in early pregnancy. Thyroid 24:1533–1540CrossRef
86.
Gianetti E, Russo L, Orlandi F, Chiovato L, Giusti M, Benvenga S, Moleti M, Vermiglio F, Macchia PE, Vitale M, Regalbuto C, Centanni M, Martino E, Vitti P, Tonacchera M (2015) Pregnancy outcome in women treated with methimazole or propylthiouracil during pregnancy. J Endocrinol Invest 38:977–985PubMedCrossRef
87.
Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, Rivkees SA (2013) Prevalence of thyrotoxicosis, antithyroid drug use and neonatal outcomes within an integrated healthcare delivery system. Thyroid 23:758–765PubMedPubMedCentralCrossRef
88.
Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Seiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Musaka K, Ito K (2012) Treatment of Graves’ disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. J Clin Endocrinol Metab 97:2396–2403PubMedCrossRef
89.
Laurberg P, Linding Andersen S (2015) Antithyroid drug use in pregnancy and birth defects: why some studies find clear associations, and some studies report none. Thyroid 25:1185–1190PubMedCrossRef
90.
Rivkees SA, Mattison DR (2009) Ending propylthiouracil-induced liver failure in children. N Engl J Med 360:1574–1575PubMedCrossRef
91.
Havgaard Kjaer R, Smedegard Hansen M, Hansen D (2015) Increasing incidence of juvenile thyrotoxicosis in Denmark. A nationwide study, 1998–2012. Horm Res Paediatr 84:102–107PubMedCrossRef
92.
Read CH Jr, Tansey MJ, Menda Y (2004) A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves’ patients. J Clin Endocrinol Metab 89:4229–4233PubMedCrossRef
93.
Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, Roman SA (2008) Clinical and economic outcomes of thyroid and parathyroid surgery in children. J Clin Endocrinol Metab 93:3058–3065PubMedCrossRef
94.
Weetman AP (2014) Graves’ disease following immune reconstitution or immunomodulatory treatment: should we manage it any differently? Clin Endocrinol (Oxf) 80:629–632CrossRef
95.
Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, Weetman A, Hale G, Chatterjee VK, Waldmann H, Compston A (1999) Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 354:1691–1695PubMedCrossRef
96.
Cossburn M, Pace AA, Jones J, Ali R, Ingram C, Baker K, Hirst C, Zajicek J, Scolding N, Boggild M, Pickersgill T, Ben-Shlomo Y, Coles A, Robertson NP (2011) Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology 77:573–579PubMedCrossRef
97.
Jubault V, Penfornis A, Schillo F, Hoen B, Izembart M, Timsit J, Kazatchkine MD, Gilquin J, Viard J-P (2000) Sequential occurrence of thyroid autoantibodies and Graves’ disease after immune restoration in severely immunocompromised human immunodeficiency virus-1-infected patients. J Clin Endocrinol Metab 85:4254–4257PubMed
98.
Chen F, Day SL, Metcalfe RA, Sethi G, Kapembwa MS, Brook MG, Churchill D, de Ruiter A, Robinson S, Lacey CJ, Weetman AP (2005) Characteristics of autoimmune thyroid disease occurring as a late complication of immune reconstitution in patients with advanced human immunodeficiency virus (HIV) disease. Medicine 84:98–106PubMedCrossRef
99.
Tailor IK, Akil M, Rennie I, Ross RJ, Snowden JA (2012) Reconstitution Graves’ disease following autologous haematopoietic stem cell transplantation for severe diffuse systemic sclerosis. Q J Med 105:369–371CrossRef
100.
Sinha A, Abinun M, Gennery AR, Barge D, Slatter M, Cheetam T (2013) Graves’ immune reconstitution inflammatory syndrome in Childhood. Thyroid 23:1010–1014PubMedCrossRef
101.
Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH (2014) Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis. J Clin Endocrinol Metab 99:80–89PubMedCrossRef
102.
Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DAS, For the CARE-MS investigators (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet 380:1819–1828PubMedCrossRef
Metadaten
Titel
Management of hyperthyroidism due to Graves’ disease: frequently asked questions and answers (if any)
verfasst von
L. Bartalena
L. Chiovato
P. Vitti
Publikationsdatum
01.10.2016
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 10/2016
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-016-0505-x

Weitere Artikel der Ausgabe 10/2016

Journal of Endocrinological Investigation 10/2016 Zur Ausgabe

Original Article

Plasma total oxidant and antioxidant status after oral glucose tolerance and mixed meal tests in patients with polycystic ovary syndrome

Original Article

Effects of crocin and voluntary exercise, alone or combined, on heart VEGF-A and HOMA-IR of HFD/STZ induced type 2 diabetic rats

Review

Reappraisal of the indication for radioiodine thyroid ablation in differentiated thyroid cancer patients

Letter to the Editor

Authors' reply

Original Article

The anti-estrogenic activity of indole-3-carbinol in neonatal rat osteoblasts is associated with the estrogen receptor antagonist 2-hydroxyestradiol

Review

Epigenetics: spotlight on type 2 diabetes and obesity

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise